Archive
Past newsletters of MDDR.
Past newsletters of MDDR.
Past newsletters of MDDR.
Saturday, 11 July 2026
The Pharmacovigilance Risk Assessment Committee (PRAC) has released new safety information regarding desogestrel- and etonogestrel-containin
Friday, 10 July 2026
The Australian Institute of Health and Welfare (AIHW) emphasises the need for better data coordination in general practice to address the si
Thursday, 9 July 2026
The Pharmaceutical Benefits Advisory Committee has revoked special dispensation allowing GPs to initiate PBS-eligible adrenaline prescriptio
Wednesday, 8 July 2026
Two non-invasive tests have been recommended by the National Institute for Health and Care Excellence (NICE) to expedite the diagnosis of en
Tuesday, 7 July 2026
A new report from the Sax Institute reveals significant uncertainties regarding the evidence supporting pharmacist-led prescribing in Austra
Monday, 6 July 2026
The authors of a correspondence in The Lancet address the proposal to rename polycystic ovary syndrome (PCOS) to polyendocrine metabolic ova
Sunday, 5 July 2026
Helena J Teede and colleagues propose renaming polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) based on
Saturday, 4 July 2026
Indivior will withdraw Sublocade, a slow-release buprenorphine injection, from the PBS in January, citing a commercial decision. This move h
Friday, 3 July 2026
Registered nurse prescribers in Australia gained the authority to prescribe Pharmaceutical Benefits Scheme (PBS) medicines, marking a signif
Thursday, 2 July 2026
The Minns government in New South Wales has proposed new driving laws for patients using THC-containing medicinal cannabis products. The Bil